DCLK3 and chronic kidney disease: Our study explored the potential of CLR as a novel biomarker for predicting the prevalence of CKD, reflecting both chronic inflammation and immune dysregulation in CKD patients, compared to traditional markers such as CRP, cytokines, TNF receptor-1, TNF receptor-2, and other individual markers (47, 48).